SubHero Banner
Text

March 2022

Core topics in this month’s edition include:

  • Adlarity (donepezil) - new drug approval
  • Revlimid (lenalidomide) - first time generic 
  • COVID-19 vaccines - expanded emergency use authorization
  • Symjepi (epinephrine) - drug recall

Download PDF

Text